Natco Pharma announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market on October 19, 2026. The launch is executed by its wholly owned subsidiary, Natco Pharma USA LLC, in collaboration with Teyro Labs Pvt Ltd based in Chennai. This move aims to address a critical supply shortage of the drug in the United States.

Product indications and market size

Carboplatin Injection is indicated for the treatment of advanced ovarian carcinoma. Its clinical applications include first-line combination therapy and palliative treatment for recurrent disease following prior chemotherapy. According to industry sales data, the product recorded estimated sales of $27.8 million in the U.S. for the 12 months ending June 2026.

Strategic context for oncology portfolio

Natco Pharma operates as a research and development oriented entity with a strong focus on oncology. The company maintains nine manufacturing sites and two R&D facilities in India, with approvals from regulatory bodies including the US FDA, Brazil ANVISA, Health Canada, and WHO. These facilities support distribution across more than 50 global markets.

What the numbers show

The disclosed estimated sales figure of $27.8 million for the trailing 12 months provides a baseline for the addressable market Natco is entering. By launching a generic version amidst a stated critical shortage, the company positions itself to capture immediate demand where supply constraints exist. The collaboration with Teyro Labs leverages external manufacturing capacity, allowing Natco to expand its oncology footprint without necessarily expanding its own immediate production overheads for this specific molecule.

Natco Pharma promoter V.C. Nannapaneni created a pledge on 8,50,000 equity shares of the company in favor of Bajaj Financial Securities Limited. The transaction was reported to the stock exchanges on October 12, 2026, with the pledge creation date recorded as October 9, 2026.

The encumbrance covers shares with a face value of ₹2 each. This specific pledge accounts for 0.47% of the company's total share capital. Prior to this event, the promoter held no encumbered shares, indicating this is a new addition to the promoter's pledged holdings.

Shareholding and Encumbrance Details

The disclosure highlights the shift in the promoter's holding status from unencumbered to partially pledged. The following table summarizes the key metrics associated with this corporate action:

Regulatory Compliance

This disclosure was made under Regulation 31(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It also complies with Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing confirms that the encumbrance type is a pledge, distinct from other forms such as lien or non-disposal undertakings.

What the Numbers Show

The pledge represents approximately 3.03% of the promoter's total holding in Natco Pharma. While the absolute number of shares is significant, the impact on the overall promoter stake remains contained, as the pledged portion constitutes less than half a percent of the company's total share capital. The beneficiary, Bajaj Financial Securities Limited, now holds security interest over these specific shares until the encumbrance is released or invoked.